SAN DIEGO, Aug. 16 /PRNewswire/ -- Medinox, Inc. in Carlsbad, California and PUMC Pharmaceutical Company in Beijing, China announce today that they have entered into a partnering agreement to develop and market NOX-100 for treating septic shock patients in China and South Korea. Under the terms of the agreement, PUMC is responsible for registration, reimbursement, manufacturing and marketing of NOX-100 in the territories. Medinox will receive milestone payments and a royalty on commercialized product.
NOX-100, also known as Norathiol(TM), is the first in a series of proprietary small molecule anti-nitric oxide (NO) agents that Medinox has created. Medinox completed a Phase 1/2 trial of NOX-100 in the U.S., in January 2004. The results of this trial in patients with severe septic shock indicate a beneficial effect for NOX-100 with a possible survival advantage and an excellent safety profile. These NO neutralizers represent a novel therapeutic approach by removing the dangerously overproduced NO in inflamed tissues while sparing the low levels of NO in normal tissues that are vitally necessary for many ongoing organ functions.
Septic shock results from the systemic immune response to infection or trauma, often leading to multi-organ failure and death. It is estimated that the number of septic shock patients in the US and China are 600,000 and 2 million per year, respectively, with a mortality rate of about 50%.
"Through this collaboration, Medinox and PUMC expect to launch the NOX-100 septic shock drug in Asian markets in four years," said Monte Lai, PhD, CEO of Medinox. He added, "This will enable us to plan further development of the product in the U.S. We value PUMC as the partner of choice in China, which is one of the largest pharmaceutical markets in the world."
The Chairman of PUMC, Mr. Raymond Su, commented, "NOX-100 may prove to be the first breakthrough for the treatment of septic shock. We are pleased that Medinox entrusted us to develop this exciting product and we look forward to collaborating with them as we move this product toward the market."
About Medinox --
Medinox is the leader in anti-NO therapeutics and is developing a broad technology platform to address a wide variety of unmet medical needs including septic chock, acute respiratory distress syndrome (including SARS) and hemorrhagic shock. In addition to its NO technology, Medinox is also developing new and safer NSAID prodrugs and MX-1520, a unique therapeutic for sickle cell anemia. For information about Medinox and its products, please visit the Company's website at http://www.medinox.com/, or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc., at (760) 603-8989, or by email at firstname.lastname@example.org.
About PUMC --
PUMC Pharmaceuticals is owned by investors in the U.S. and by the Chinese Academy of Medicine, the highest medical authority in China with five major teaching hospitals and thirteen research institutes, and forges extensive connections at all levels of the government, the medical community, and the patient population. They currently market products for the gastroenterology and anesthesia markets, and are developing products for indications including oncology, renal failure, neurology and critical care. Mr. Raymond Su can be contacted in Beijing at (86-10) 6581-7148. PUMC's website can be viewed at http://www.pumc-pharm.com/.